为进一步加强与投资者的互动交流，淄博齐翔腾达化工股份有限公司（以下 简称"公司"）将参加由山东证监局、山东上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年山东辖区上市公司投资者网上集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演 APP,参与本次互动交流。活动时间为 2025 年 5 月 15 日（周四）15:00-16:30。 届时公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、 融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交 流，欢迎广大投资者踊跃参与！ 证券代码：002408 证券简称：齐翔腾达 公告编号：2025-029 债券代码：128128 债券简称：齐翔转 2 淄博齐翔腾达化工股份有限公司 关于参加 2025 年山东辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特此公告。 淄博齐翔腾达化工 ...

Market Performance - The Shanghai Composite Index and Shenzhen Component Index experienced declines of 0.30% and 0.69% respectively on May 5, 2025, while the ChiNext Index and STAR Market 50 fell by 0.87% and 1.96% respectively [1] - Among 33 A-share companies in Zibo, 30 saw an increase, 1 remained flat, and 2 declined during the same period [1] Notable Stock Movements - Weiming Pharmaceutical (002581) achieved a remarkable 23.29% increase over five days, leading the gains [1] - Yahua Electronics (301337) and Jincheng Pharmaceutical (300233) also saw significant increases of 17.30% and 11.31% respectively [1] - On May 7, PEEK material concept stocks surged, with Zhongxin Fluorine Materials (002915) hitting the daily limit for the sixth time in nine days, and Kaisheng New Materials (301069) rising by 2.29% with a trading volume of 4.02 billion yuan [1] Company Announcements - Kehui Co., Ltd. announced a share repurchase plan with a budget between 9 million and 16 million yuan, with a maximum repurchase price of 17 yuan per share, aimed at employee stock ownership plans [1] Financial Results - Furuida (600223) reported a revenue of 526 million yuan in its cosmetics segment for Q1 2025, with a gross margin of 61.06% [3] - Qichang Tenda (002408) achieved total revenue of 5.618 billion yuan in Q1 2025, a year-on-year increase of 2.53%, but saw a significant drop in net profit by 83.18% to 5.4007 million yuan [3] - Xinhua Medical (600587) reported a total revenue of 2.308 billion yuan, down 8.74% year-on-year, with a net profit decline of 23.97% to 160 million yuan [3] - Bohui Paper (600966) reported a total revenue of 4.564 billion yuan, a 3.77% increase year-on-year, but a net profit decline of 46.91% to 53.3737 million yuan [3] Market Capitalization - In terms of market capitalization, Yingke Medical (300677) led with 14.708 billion yuan, followed closely by Shandong Pharmaceutical Glass (600529) at 14.626 billion yuan, and Qichang Tenda (002408) at 12.963 billion yuan [4]

Core Insights - The total revenue of 33 A-share listed companies in Zibo for 2024 is approximately 147.77 billion yuan, with 23 companies showing revenue growth compared to the previous year [1][2] - The total net profit for these companies is around 6.66 billion yuan, with 19 companies experiencing a year-on-year increase in net profit [1][8] Revenue Performance - 23 companies achieved positive revenue growth, while 10 companies reported declines [2] - Three companies surpassed the 10 billion yuan revenue mark: Qixiang Tengda (25.22 billion yuan), Bohui Paper (18.93 billion yuan), and Xinhua Medical (10.02 billion yuan) [2][4] - Qixiang Tengda remains the revenue leader despite a 6.31% decline in revenue [4] - Bohui Paper produced 4.53 million tons of paper, achieving a revenue of 18.93 billion yuan, a 1.27% increase [4] - Xinhua Medical's revenue increased slightly by 0.09%, with significant growth in its pharmaceutical equipment segment [4][5] Profitability Analysis - The total net profit of 33 companies is approximately 6.66 billion yuan, with notable profit leaders being Yingke Medical (1.47 billion yuan), Shandong Yaobang (943 million yuan), and Xinhua Medical (692 million yuan) [8][9] - Yingke Medical's net profit surged by 282.63%, marking it as the most profitable company [9][10] - 19 companies reported an increase in net profit, while 14 companies experienced declines [8][12] - Five companies saw net profit declines exceeding 50%, with Yahua Electronics reporting a significant loss of 26 million yuan [12][13] Notable Companies - Yingke Medical's production capacity utilization reached 100%, with a recovery in sales prices compared to 2023 [10] - Bohui Paper's strong production capacity contributed to its stable revenue growth [4] - Xinhua Medical is expanding its international presence with five overseas sales centers [5] - Blue Sail Medical, despite a revenue increase of 26.91%, reported a loss of 446 million yuan [16]

| 证券代码：002408 | 证券简称：齐翔腾达 | 公告编号：2025-028 | | --- | --- | --- | | 债券代码：128128 | 债券简称：齐翔转2 | | 淄博齐翔腾达化工股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会未出现否决议案的情形。 2.本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议的召开和出席情况 1、会议召集人:公司第六届董事会 2、本次股东大会现场会议召开时间:2025 年 5 月 9 日下午 14:00； 通过深圳证券交易所互联网投票系统投票时间:2025年5月9日9:15-15:00期 间的任意时间； 通过深圳证券交易所交易系统进行网络投票时间:2025年5月9日上午 9:15-9:25，9:30—11:30，下午13:00—15:00。 3、会议地点：山东省淄博市临淄区杨坡路 206 号 18 楼会议室。 4、会议方式：采取现场投票与网络投票相结合的方式。 5、主持人：公司董事长李庆文先生。 6、本次会议的召集、召开程序符 ...

会社律师事务所 KING&WODD VALLESONS 北京市朝阳区东三环中路1号 环球金融中心办公楼东楼18层 8th Floor, Fast Tower, World Financial Dongsanhuan Zhonglu. Chaovang District Beijing, 100020 P.R. China +86 10 5878 5588 北京市金杜律师事务所 关于淄博齐翔腾达化工股份有限公司 2024年度股东大会 之法律意见书 致:淄博齐翔腾达化工股份有限公司 北京市金杜律师事务所(以下简称本所)接受淄博齐翔腾达化工股份有限 公司(以下简称公司)委托,根据《中华人民共和国证券法》(以下简称《证券 法》)、《中华人民共和国公司法》(以下简称《公司法》)、中国证券监督管理委 贝会《上市公司股东会规则》(以下简称《股东会规则》等中华人民共和国境 内(以下简称中国境内,为本法律意见书之目的,不包括中国香港特别行政区、 中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规章、规 范性文件和现行有效的《淄博齐翔腾达化工股份有限公司章程》(以下简称《公 司章程》)有关规定,指派律师出席了公司于 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [8]. Core Views - The company reported a first-quarter revenue of 5.618 billion yuan in 2025, representing a year-on-year increase of 2.53% but a quarter-on-quarter decrease of 18.18%. The net profit attributable to the parent company was 0.05 billion yuan, down 83.18% year-on-year but turning profitable quarter-on-quarter. The non-recurring net profit attributable to the parent company was 0.06 billion yuan, down 80.38% year-on-year but also turning profitable quarter-on-quarter [2][6]. Summary by Sections Company Overview - The company is a leader in the C4 industrial chain, focusing on deep processing of raw material carbon four, with four product lines including butene, isobutylene, butane, and isobutane. It has a strong market position with a 70% share in the domestic market for its main product, methyl ethyl ketone [12]. Industry Analysis - The butadiene chain is maintaining a good level of prosperity, with the industry capacity utilization rate around 70% due to supply constraints. The company uses the largest butene oxidation method in the country to produce butadiene, which aligns with its existing industrial chain [12]. Financial Performance - The company expects significant improvement in operating conditions due to a decrease in raw material prices starting from the second quarter of 2025. The projected net profits for 2025, 2026, and 2027 are 0.32 billion yuan, 0.76 billion yuan, and 1.21 billion yuan, respectively, with corresponding price-to-earnings ratios of 39.4, 16.6, and 10.4 [12][19].

Core Viewpoint - The company emphasizes the accuracy and completeness of its quarterly report, ensuring no false statements or significant omissions are present [2][3]. Financial Data - The first quarter report is not audited [3]. - The company issued 29.9 million convertible bonds with a total issuance amount of 2,990,000,000.00 yuan, netting 2,966,543,311.66 yuan after deducting fees [4]. - As of March 31, 2025, the remaining amount of the convertible bonds "齐翔转2" is 679,395,600 yuan, with 6,793,956 bonds remaining [4]. Shareholder Information - The report includes details on the total number of common shareholders and the top ten shareholders' holdings [3]. Other Important Matters - The company received approval from the China Securities Regulatory Commission for the public issuance of convertible bonds [4].

Revenue and Profitability - Revenue for Q1 2025 was CNY 5,618,126,945.15, an increase of 2.53% compared to CNY 5,479,652,158.91 in the same period last year[4] - Net profit attributable to shareholders decreased by 83.18% to CNY 5,400,734.72 from CNY 32,101,763.00 year-on-year[4] - Basic earnings per share dropped by 80.00% to CNY 0.002 from CNY 0.01 in the previous year[4] - Total operating revenue for the current period reached ¥5,618,126,945.15, an increase from ¥5,479,652,158.91 in the previous period, representing a growth of approximately 2.5%[16] - Net profit for the current period was ¥9,276,064.81, down from ¥27,345,827.65 in the previous period, indicating a decline of approximately 66%[17] - The company's operating profit decreased significantly to ¥11,427,715.62 from ¥46,795,566.86, a drop of around 75%[17] - The net profit attributable to the parent company was CNY 20,757,923.88, down from CNY 36,714,295.70 year-over-year[18] - Basic and diluted earnings per share were both CNY 0.002, compared to CNY 0.01 in the previous period[18] Cash Flow - Net cash flow from operating activities fell by 31.81% to CNY 242,092,793.66 compared to CNY 355,029,709.00 in Q1 2024[4] - Cash inflows from operating activities totaled CNY 6,183,156,212.98, an increase from CNY 6,065,938,433.24 in the prior period[19] - Cash outflows from operating activities were CNY 5,941,063,419.32, compared to CNY 5,710,908,724.24 previously[20] - Cash flow from investing activities resulted in a net outflow of CNY 211,977,369.23, compared to CNY 516,346,087.85 in the previous period[20] - Cash flow from financing activities showed a net outflow of CNY 129,942,986.05, compared to a net inflow of CNY 340,782,710.76 in the prior period[20] - The ending cash and cash equivalents balance was CNY 1,563,293,753.47, down from CNY 1,318,744,309.91 in the previous period[20] Assets and Liabilities - Total assets increased by 0.48% to CNY 25,481,861,371.52 from CNY 25,361,163,761.87 at the end of the previous year[4] - Total liabilities increased to ¥13,572,156,979.36 from ¥13,483,889,008.17, reflecting a rise of about 0.7%[14] - The company's equity attributable to shareholders rose to ¥11,755,331,055.19 from ¥11,666,132,823.86, an increase of approximately 0.8%[14] - The company reported a significant increase in accounts payable, which rose to ¥1,720,259,402.24 from ¥1,307,129,137.88, indicating a growth of approximately 31.6%[14] Shareholder Information - Total number of common shareholders at the end of the reporting period was 61,121[9] - The largest shareholder, Shandong Energy Group New Materials Co., Ltd., holds 53.18% of shares, totaling 1,511,964,163 shares[9] - The second largest shareholder, Chang'an International Trust Co., Ltd., holds 75,386,218 shares[9] - The company has 22,794,413 shares held in a repurchase special account, representing 0.80% of the total share capital[10] - The number of shares held by the top ten shareholders participating in margin trading includes 13,571,505 shares by Mei Jingming and 12,350,140 shares by Wang Huirong[10] Investment and Expenses - Cash flow from investment activities decreased by 59.09% to CNY 211,977,369.23, reflecting reduced investment in new projects[7] - Management expenses decreased by 64.06% to CNY 78,567,013.26, due to reclassification of shutdown costs to operating costs[7] - Research and development expenses rose to ¥172,827,392.05, compared to ¥148,333,868.07, marking an increase of about 16.5%[17] - The company reported a significant increase of 1138.03% in trading financial assets, reaching CNY 45,785,998.02 due to increased derivative investments[7] - The company has a total of 45,785,998.02 RMB in trading financial assets, up from 3,698,290.63 RMB[12]

Group 1: Market Position and Strategy - The company maintains a market share of approximately 70% in the domestic acetone market and over 65% in the export market [3] - No new production capacity is expected in the acetone industry for 2024-2025, with stable overall market demand anticipated [2] - The company has implemented over 120 technical innovations to reduce acetone production costs, maintaining a low-cost strategy [3] Group 2: Financial Performance and Growth - The financial data for Q1 2025 is still being compiled and will be disclosed on April 30, 2025 [4] - Ongoing projects include a 200,000 tons/year isononanol project and 16 investment-efficient technical improvement projects, which are expected to enhance overall profitability [5] Group 3: Future Development and Industry Outlook - The company plans to develop a carbon three industrial chain focusing on new materials, leveraging existing propylene conditions [6] - Emphasis on high-value fine chemical products through a new R&D center and collaboration with research institutions [7] - The petrochemical industry faces both challenges and opportunities, with increasing demand for high-performance chemical materials driven by global population growth and economic development [7] Group 4: Risk Management and Export Strategy - Exchange rate fluctuations impact export product profits, with the company employing foreign exchange options and forward contracts to mitigate risks [7] - The company has seen significant growth in export volume and revenue for 2024, adjusting sales strategies based on various market factors [7] - Currently, the company does not export directly to the U.S., focusing instead on East Asia, Southeast Asia, South America, and Europe [7]

| 证券代码：002408 | 证券简称：齐翔腾达 | 公告编号：2025-025 | | --- | --- | --- | | 债券代码：128128 | 债券简称：齐翔转 2 | | 淄博齐翔腾达化工股份有限公司 第六届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会召开情况 淄博齐翔腾达化工股份有限公司(以下简称"公司")第六届董事会第二十次会议 通知于 2025 年 4 月 10 日以电子邮件和专人送达方式向全体董事发出，会议于 2024 年 4 月 14 日以通讯方式召开，应参会董事 9 名，实际参会董事 9 名。公司监事列席 了会议。本次会议由董事长李庆文先生主持，会议的召集、召开程序符合《公司法》 和《公司章程》的规定。 二、董事会审议情况 审议通过了《关于不向下修正"齐翔转 2"转股价格的议案》 表决结果：9 票同意，0 票反对，0 票弃权，0 票回避 经审议，董事会决定本次不向下修正"齐翔转 2"转股价格，且自本次董事会审 议通过之日起未来三个月内（2025 年 4 月 14 日至 2025 年 7 月 ...